윌슨병 환자에서 Penicillamine 복용 후 발생한 독성표피괴사용해증 1예
Penicillamine-induced toxic epidermal necrolysis in a patient with Wilson disease
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Toxic epidermal necrolysis (TEN) is rare but life-threatening severe cutaneous adverse reaction, which is mostly induced by drugs. It characterized by widespread epidermal necrosis, resulting in bullae with sloughing and frequent involvement of the mucous membrane. Due to high mortality, management of patients requires prompt withdrawal of the causative drug, appropriate supportive care, and consideration of immune-modulating agents, such as intravenous immunoglobulin or corticosteroids. Wilson disease is an inherited disorder of copper transport that results in excessive accumulation of copper in the body. Copper chelation with penicillamine is an effective first line therapy in most patients. We present a 20-year-old man with Wilson disease who developed TEN following administration of penicillamine. He was successfully treated with systemic corticosteroid, intravenous immunoglobulin, and supportive management.
Abstract
Toxic epidermal necrolysis (TEN) is rare but life-threatening severe cutaneous adverse reaction, which is mostly induced by drugs. It characterized by widespread epidermal necrosis, resulting in bullae with sloughing and frequent involvement of the mucous membrane. Due to high mortality, management of patients requires prompt withdrawal of the causative drug, appropriate supportive care, and consideration of immune-modulating agents, such as intravenous immunoglobulin or corticosteroids. Wilson disease is an inherited disorder of copper transport that results in excessive accumulation of copper in the body. Copper chelation with penicillamine is an effective first line therapy in most patients. We present a 20-year-old man with Wilson disease who developed TEN following administration of penicillamine. He was successfully treated with systemic corticosteroid, intravenous immunoglobulin, and supportive management.
참고문헌 (15)
- Pereira FA, "Toxic epidermal necrolysis", J Am Acad Dermatol, 56, pp.181~200 (2007)
- Roujeau JC, "Severe adverse cutaneous reactions to drugs", N Engl J Med, 331, pp.1272~1285 (1994)
- Roujeau JC, "Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis", N Engl J Med, 333, pp.1600~1607 (1995)
- Downey A, "Toxic epidermal necrolysis: review of pathogenesis and management", J Am Acad Dermatol, 66, pp.995~1003 (2012)
- Seo JK, "Wilson disease: an update", Korean J Hepatol, 12, pp.333~363 (2006)
- Levy RS, "Penicillamine: review and cutaneous manifestations", J Am Acad Dermatol, 8, pp.548~558 (1983)
- Ishak R, "Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects", Am J Clin Dermatol, 14, pp.223~233 (2013)
- Letko E, "Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature", Ann Allergy Asthma Immunol, 94, pp.419~436 (2005)
- Bastuji-Garin S, "Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme", Arch Dermatol, 129, pp.92~96 (1993)
- Viard I, "Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin", Science, 282, pp.490~493 (1998)
- Abe R, "Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand", Am J Pathol, 162, pp.1515~1520 (2003)
- Trent J, "Toxic epidermal necrolysis and intravenous immunoglobulin: a review", Semin Cutan Med Surg, 25, pp.91~93 (2006)
- Bastuji-Garin S, "SCORTEN: a severity-of-illness score for toxic epidermal necrolysis", J Invest Dermatol, 115, pp.149~153 (2000)
- Roberts EA, "Division of Gastroenterology and Nutrition, Hospital for Sick Children, Toronto, Ontario, Canada. A practice guideline on Wilson disease", Hepatology, 37, pp.1475~1492 (2003)
- Greer KE, "Skin lesions induced by penicillamine. Occurrence in a patient with hepatolenticular degeneration (Wilson Disease)", Arch Dermatol, 112, pp.1267~1269 (1976)